Compared with lower-grade glioma (WHO II and WHO III), Orai2 expression was significantly increased in GBM from the TCGA dataset (Student's t-test, P < 0.001) (Figure 1(c)). This evidence concerns the gene ORAI2 and central nervous system cancer.